Fundraising FoxDynocardia
Newton Centre, US · Founded 2018 · Delaware corporation
Find your way into Dynocardia
Sign up to see every warm intro you have to Dynocardia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dynocardia team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dynocardia develops ViTrack, a wearable and connected platform for continuous monitoring of blood pressure and other vital heart and lung functions. The technology targets applications across hospitals, clinical practice, remote patient monitoring, and consumer wellness.
Founders & leadership
Dynocardia was founded in 2018 by Mohan Thanikachalam.
MT
Mohan ThanikachalamCEO, President, and Co-FounderMohan Thanikachalam is a cardiovascular surgeon with over 15 years of clinical experience and co-founder and CEO of Dynocardia, which develops ViTrack, a cuff-less wearable platform for continuous blood pressure and vital sign monitoring. He has served as affiliate faculty at MIT and research assistant professor at Tufts University School of Medicine, and previously established cardiovascular disease prevention and management programs using point-of-care and mobile health technologies.
EA
Edward Adelson, PhDCo-founder & Core Technology Team Member
AB
Abhijit Biswas, PhDCo-founder and CTO
Reported raises · per SEC filings
Form D private placements$7.4M disclosed across 4 rounds · 2019–2025
▶$1.2MraisedDec 2025 · 20 investors · Other Health CareRule 506(b)
▶$1.2MraisedDec 2025 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mohan ThanikachalamExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.2M
- Sales commissions
- $74.4K
- Finders' fees
- $24.8K
- Placement agents
- American Trust Investment Services, Inc.
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.7MraisedJan 2025 · 35 investors · Other Health CareRule 506(b)
▶$3.7MraisedJan 2025 · 35 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mohan ThanikachalamExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $3.7M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJan 2021 · 19 investors · Other Health CareRule 506(b)
▶$2MraisedJan 2021 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mohan ThanikachalamExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2M
- Sales commissions
- $12.5K
- Placement agents
- Revere Securities LLC
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$490KraisedOct 2020 · 7 investors · Other Health CareRule 506(b)
▶$490KraisedOct 2020 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mohan ThanikachalamExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $490K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
ToperaAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Zendesk New YorkThis is Zendesk's internal belonging/diversity and inclusion program page, not a company profile page for an external company. It describes Zendesk's internal culture initiatives and leadership development programs.
SymKardiaSymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.
Companies working in the same space as Dynocardia.
Frequently asked questions
- What does Dynocardia do?
- Dynocardia develops ViTrack, a wearable and connected platform for continuous monitoring of blood pressure and other vital heart and lung functions. The technology targets applications across hospitals, clinical practice, remote patient monitoring, and consumer wellness.
- Who founded Dynocardia?
- Dynocardia was founded by Mohan Thanikachalam in 2018.
- How much funding has Dynocardia raised?
- Dynocardia has disclosed $7.4M raised across 4 rounds.
- Where is Dynocardia headquartered?
- Dynocardia is headquartered in Newton Centre, US.